Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor

Clinical Infectious Diseases

Volumn 60, Issue 5, 2015, Pages 703-712

  Heltshe, Sonya L ^a,b   Mayer Hamblett, Nicole ^a,b   Burns, Jane L ^a,c   Khan, Umer ^b   Baines, Arthur ^b   Ramsey, Bonnie W ^a,b   Rowe, Steven M ^d  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Coordinating Center ^*  (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

CFTR modulator; Cystic fibrosis; Ivacaftor; P. aeruginosa

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR; AMINOPHENOL DERIVATIVE; ENZYME ACTIVATOR; MUTANT PROTEIN; QUINOLONE DERIVATIVE;

ARTICLE; BACTERIUM CULTURE; BODY MASS; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CYSTIC FIBROSIS; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENE MUTATION; HAEMOPHILUS INFLUENZAE; HOSPITALIZATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; NONHUMAN; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; TREATMENT DURATION; ADOLESCENT; ADULT; AGED; AMINO ACID SUBSTITUTION; ASPERGILLUS; COMPLICATION; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MISSENSE MUTATION; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; AMINOPHENOLS; ASPERGILLUS; CHILD; COHORT STUDIES; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENZYME ACTIVATORS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUTANT PROTEINS; MUTATION, MISSENSE; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUINOLONES; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84935511737     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu944     Document Type: Article

References (47)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352:1992-2001.
2. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med 2010; 363:1991-2003.
3. Gibbs GE. Sweat tests for diagnosis of cystic fibrosis. Q Rev Pediatr 1958; 13:188-91.
4. Ramsey BW, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011; 365:1663-72.
5. Kerem E, CoreyM, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr 1990; 116:714-9.
6. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995; 19:10-5.
7. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001; 32:277-87.
8. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992; 12:158-61.
9. Rowe SM, Heltshe SL, Gonska T, et al. Clinical mechanism of the CFTR potentiator ivacaftor in G551D-mediated cystic fibrosis. Am J Respir Crit Care Med 2014; 190:175-84.
10. Cystic Fibrosis Foundation Patient Registry: Annual data report 2012. Bethesda, MD: Cystic Fibrosis Foundation, 2012.
11. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957-69.
12. Saiman L, Siegel J. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003; 24(5 suppl):S6-52.
13. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003; 2:29-34.
14. Wang X, Dockery DW, Wypij D, et al. Pulmonary function growth velocity in children 6 to 18 years of age. Am Rev Respir Dis 1993; 148(6 pt 1):1502-8.
15. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999; 159:179-87.
16. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007; 19:83-8.
17. Imundo L, Barasch J, Prince A, Al-Awqati Q. Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. Proc Natl Acad Sci U S A 1995; 92:3019-23.
18. Pier GB. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to Pseudomonas aeruginosa infections. Proc Natl Acad Sci U S A 2000; 97:8822-8.
19. Kong F, Young L, Chen Y, et al. Pseudomonas aeruginosa pyocyanin inactivates lung epithelial vacuolar ATPase-dependent cystic fibrosis transmembrane conductance regulator expression and localization. Cell Microbiol 2006; 8:1121-33.
20. Schroeder TH, Lee MM, Yacono PW, et al. CFTR is a pattern recognition molecule that extracts Pseudomonas aeruginosa LPS from the outer membrane into epithelial cells and activates NF-kappa B translocation. Proc Natl Acad Sci U S A 2002; 99:6907-12.
21. Pezzulo AA, Tang XX, Hoegger MJ, et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012; 487:109-13.
22. Reznikov LR, Abou Alaiwa MH, Dohrn CL, et al. Antibacterial properties of the CFTR potentiator ivacaftor. J Cyst Fibros 2014; 13:515-9.
23. Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006; 8:933-44.
24. Kraemer R, Delosea N, Ballinari P, Gallati S, Crameri R. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:1211-20.
25. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23:299-323.
26. Pihet M, Carrere J, Cimon B, et al. Occurrence and relevance of filamentous fungi in respiratory secretions of patients with cystic fibrosis- a review. Med Mycol 2009; 47:387-97.
27. Sagel SD, Harris JK,Wagner BD, et al. Effects of ivacaftor on airway microbiome and inflammation in G551D patients. Pediatr Pulmonol 2013; 48(S36): 285.
28. Seliger VI, Rodman D, Van Goor F, Schmelz A, Mueller P. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation. J Cyst Fibros 2013; 12:706-13.
29. Grimes DA, Schulz KF. Bias and causal associations in observational research. Lancet 2002; 359:248-52.
30. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001; 183:444-52.
31. Li Z, Kosorok MR, Farrell PM, et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 2005; 293:581-8.
32. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
33. Lee TW, Brownlee KG, Denton M, Littlewood JM, Conway SP. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 2004; 37: 104-10.
34. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009; 136:1554-60.
35. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165:847-56.
36. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros 2008; 7: 523-30.
37. Wiesemann HG, Steinkamp G, Ratjen F, et al. Placebo-controlled, doubleblind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol 1998; 25:88-92.
38. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167:841-9.
39. Mayer-Hamblett N, Kronmal RA, Gibson RL, et al. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis. Pediatr Pulmonol 2012; 47:125-34.
40. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment. Lancet 1991; 338:725-6.
41. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997; 23:330-5.
42. Parad RB, Gerard CJ, Zurakowski D, Nichols DP, Pier GB. Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun 1999; 67:4744-50.
43. Koch C. Early infection and progression of cystic fibrosis lung disease. Pediatr Pulmonol 2002; 34:232-6.
44. West SE, Zeng L, Lee BL, et al. Respiratory infections with Pseudomonas aeruginosa in children with cystic fibrosis: early detection by serology and assessment of risk factors. JAMA 2002; 287:2958-67.
45. Douglas TA, Brennan S, Gard S, et al. Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis. Eur Respir J 2009; 33:305-11.
46. McPherson H, Rosenthal M, Bush A. Can mucoid Pseudomonas aeruginosa be eradicated in children with cystic fibrosis? Pediatr Pulmonol 2010; 45:566-8.
47. Troxler RB, Hoover WC, Britton LJ, Gerwin AM, Rowe SM. Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis. Pediatr Pulmonol 2012; 47:1113-22.